Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 20/20 | 1.00 |
| ▸ | CACNA1A | O00555 | 20/20 | 1.00 |
| ▸ | CACNA1G | O43497 | 20/20 | 1.00 |
| ▸ | CACNG3 | O60359 | 20/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 20/20 | 1.00 |
| ▸ | CACNA1H | O95180 | 20/20 | 1.00 |
| ▸ | CACNB3 | P54284 | 20/20 | 1.00 |
| ▸ | CACNA2D1 | P54289 | 20/20 | 1.00 |
| ▸ | CACNG7 | P62955 | 20/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 20/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 20/20 | 1.00 |
| ▸ | CACNB1 | Q02641 | 20/20 | 1.00 |
| ▸ | CACNG1 | Q06432 | 20/20 | 1.00 |
| ▸ | CACNB2 | Q08289 | 20/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 20/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 20/20 | 1.00 |
| ▸ | CACNA1E | Q15878 | 20/20 | 1.00 |
| ▸ | CACNA2D4 | Q7Z3S7 | 20/20 | 1.00 |
| ▸ | CACNA2D3 | Q8IZS8 | 20/20 | 1.00 |
| ▸ | CACNG8 | Q8WXS5 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15771367 | 0.91 | CACNB4 (1.00) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15570234 | 0.88 | CACNA1B (1.00) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15770952 | 0.88 | CACNA1B (1.00) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15771390 | 0.87 | CACNB4 (1.00) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15570141 | 0.87 | CACNB4 (1.00) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15770143 | 0.87 | CACNB4 (0.83) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15770842 | 0.87 | CACNB4 (0.77) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15770843 | 0.87 | CACNB4 (0.77) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15771060 | 0.87 | CACNB4 (0.77) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL15770141 | 0.87 | CACNB4 (1.00) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434693-B2 | Substituted pyrazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | claimed |
| EP-2885278-B1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-03 | — | — | EP | claimed |
| US-20140162997-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-12 | — | — | US | claimed |
| US-9434693-B2 | Substituted pyrazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| US-9434693-B2 | Substituted pyrazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| US-9434693-B2 | Substituted pyrazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| EP-2885278-B1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-03 | — | — | EP | disclosed |
| EP-2885278-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | Janssen Pharmaceutica N.V. (BE) | 2015-06-24 | — | — | EP | disclosed |
| US-20140162997-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-12 | — | — | US | disclosed |
| US-20140162997-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-12 | — | — | US | disclosed |
| US-20140162997-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-12 | — | — | US | disclosed |
| WO-2014028800-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162997-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1B, CACNA1A | CACNB4 34/4885CACNA1A 3/4885CACNA1G 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.